Berger MM, Shenkin A, Schweinlin A, Amrein K, Augsburger M, Biesalski HK et al (2022) ESPEN micronutrient guideline
When to stop or modify protocols Discontinue or modify protocols if symptoms worsen progressively, if new neurological symptoms develop, if allergic reactions occur, or if significant side effects emerge
The detection windows are shorter because blood concentrations drop faster than urinary metabolite concentrations for most small-molecule drugs
About this article Cite this article Chen, J.J., Thiyagarajah, M., Song, J
Cagrilintide is the first long-acting amylin analog to reach Phase 3 trials, with fatty acid acylation enabling once-weekly dosing compared to the three-times-daily dosing required by the older amylin analog pramlintide
doi: 10.1159/000104263 146 BadloeFMSde VrieseSCoolensKSchmidt-WeberCBRingJGutermuthJet al